| Protocol | Title |
|---|---|
| C80405 | A Phase III Trial of Irinotecan / 5-FU / Leucovorin or Oxaliplatin /
5-FU / Leucovorin with Bevacizumab, or Cetuximab (C225), or with the
Combination of Bevacizumab and Cetuximab for Patients with Untreated
Metastatic Adenocarcinoma of the Colon or Rectum
Activation Date: 22-sep-2005 |
| CALGB80802 | Phase III Randomized Study of Sorafenib Plus Doxorubicin Vs Sorafenib
in Patients with Advanced Hepatocellular Carcinoma (HCC)
Activation Date: 22-feb-2010 |
| E1208 | A Phase III Randomized, Double-Blind Trial of Chemoembolization with
or without Sorafenib in Unresectable Hepatocellular Carcinoma (HCC)
in Patients with and without Vascular Invasion
Activation Date: 28-oct-2009 |
| E3205 | Phase II Trial of Cetuximab Plus Cisplatin, 5-Fluorouracil and
Radiation in Immunocompetent Patients with Anal Carcinoma (Limited
institution participation)
Activation Date: 19-jan-2007 |
| E4203 | Phase II Study of Treatment Selection Based Upon Tumor Thymidylate
Synthase Expression in Previously Untreated Patients with Metastatic
Colorectal Cancer
Activation Date: 14-jul-2005 ECOG Participants(requires Adobe Acrobat) |
| E5202 | A Randomized Phase III Study Comparing 5-FU, Leucovorin and
Oxaliplatin versus 5-FU, Leucovorin, Oxaliplatin and Bevacizumab in
Patients with Stage II Colon Cancer at High Risk for Recurrence to
Determine Prospectively the Prognostic Value of Molecular Markers
Activation Date: 04-aug-2005 |
| RTOG 0436 | A Phase III Trial Evaluating the Addition of Cetuximab to Paclitaxel,
Cisplatin and Radiation for Patients With Esophageal Cancer Who Are
Treated Without Surgery
Activation Date: 08-jul-2008 |
| S0518 | A Phase III Prospective Randomized Comparison of Depot Octreotide
Plus Interferon Alpha Versus Depot Octreotide Plus Bevacizumab (NSC
#704865) in Advanced, Poor Prognosis Carcinoid Patients
Activation Date: 10-dec-2007 |
| S0600 | Phase III Trial of Irinotecan-Based Chemotherapy Plus Cetuximab
(NSC-714692) with or without Bevacizumab (NSC-704865) as Second-Line
Therapy for Patients with Metastatic Colorectal Cancer who have
Progressed on Bevacizumab with Either FOLFOX, OPTIMOX, or XELOX
Activation Date: 22-jun-2007 |
All contents copyright © 1998 Eastern Cooperative Oncology Group.
All rights reserved.
Revised: 09/02/10